AF
CRNX icon

Amalgamated Financial’s Crinetics Pharmaceuticals CRNX Stock Holding History

Amalgamated Financial’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$159K Buy
+7,228
New +$146K ﹤0.01% 1984

Other funds holding CRNX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Amalgamated Financial's CRNX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Crinetics Pharmaceuticals (CRNX) in Q1 2022: 7,228 shares worth $159K. The stake represents ﹤0.01% of the portfolio and ranks #1984 among its holdings.

116 funds tracked by Wall St. Rank hold CRNX as of Q1 2022.

  • Amalgamated Financial held 7,228 shares of Crinetics Pharmaceuticals worth $159K as of Q1 2022.
  • Crinetics Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1984 holding.
  • 116 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.